Detalles de la búsqueda
1.
Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in previously treated patients with severe haemophilia A.
Haemophilia
; 24(4): 619-627, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29855112
2.
PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.
Haemophilia
; 23(5): 697-704, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28452151
3.
Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series.
Haemophilia
; 23(2): 255-263, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28205285
4.
Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
Haemophilia
; 22(3): 374-80, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26582282
5.
Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq® ) in adults with severe haemophilia A: efficacy and safety.
Haemophilia
; 22(2): 225-231, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26315974
6.
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
Haemophilia
; 21(6): 784-90, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25990590
7.
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Haemophilia
; 20(5): 651-8, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24697870
8.
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Haemophilia
; 20(1): 15-24, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23834666
9.
Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
Haemophilia
; 19(5): 674-8, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23647607
10.
A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
Haemophilia
; 17(4): 590-6, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21299747
11.
An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
Haemophilia
; 16(2): 240-6, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20015218
12.
Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Haemophilia
; 15(6): 1243-8, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19659601
13.
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
Acta Haematol
; 119(2): 89-97, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18305381
14.
Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.
J Thromb Haemost
; 16(2): 253-261, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29220876
15.
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.
J Thromb Haemost
; 5(9): 1904-13, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17723130
16.
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
J Cancer Res Clin Oncol
; 132(2): 99-104, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16292542
17.
In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer--changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile.
Crit Rev Oncol Hematol
; 39(1-2): 125-32, 2001.
Artículo
en Inglés
| MEDLINE | ID: mdl-11418309
18.
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).
J Thromb Haemost
; 11(6): 1119-27, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23528101
19.
Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A.
Haemophilia
; 13(1): 9-11, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17212718
20.
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
Ann Oncol
; 15(9): 1413-8, 2004 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-15319248